Department of Neurology, The Second Affiliated Hospital of Guangxi Medical University, No. 166 Daxuedong Road, Nanning, Guangxi 530007, China.
Department of Neurology, The Second Affiliated Hospital of Guangxi Medical University, No. 166 Daxuedong Road, Nanning, Guangxi 530007, China.
Clin Neurol Neurosurg. 2023 Nov;234:108007. doi: 10.1016/j.clineuro.2023.108007. Epub 2023 Sep 30.
To compare the efficacy and safety of endovascular therapy (EVT) versus best medical management (BMM) in patients with acute ischemic stroke (AIS) with large infarct core.
We searched Pubmed, Embase and Cochrane Central Register of Controlled Trials for published randomized clinical trials (RCTs) from inception to February 18, 2023. We defined patients with large core infarcts as having an Alberta Stroke Program early computed tomography score (ASPECTS) of 3-5. The primary outcome was functional independence, defined as a score of 0-2 on the modified Rankin scale (mRS) at 90 days. Secondary outcome was independent ambulation defined as mRS 0-3 at 90 days. Safety outcomes were mortality at 90 days, symptomatic intracranial hemorrhage (sICH) and any intracranial hemorrhage (ICH).
The overall treatment effect was more favourable to EVT group. EVT was significantly correlated with improvement of functional independence at 90 days (mRS 0-2) (RR = 2.40; 95 % CI, 1.82-3.16; P < 0.01; I = 0 %) and independent ambulation (mRS 0-3) (RR = 1,78; 95 % CI, 1.28-2.48; P < 0.01; I = 58 %) at 90 days. 90-day mortality was not significantly different between the two groups(RR = 0.95; 95 % CI, 0.78-1.16; P > 0.05; I = 0 %). The risk of sICH and any ICH was higher in EVT group than in BMM group.
Compared with BMM, EVT may improve functional outcomes in patients with ASPECTS 3-5, despite being associated with an increased risk of sICH and any ICH.
比较血管内治疗(EVT)与最佳药物治疗(BMM)在急性缺血性脑卒中(AIS)伴大梗死核心患者中的疗效和安全性。
我们检索了 Pubmed、Embase 和 Cochrane 对照试验中心注册库,以获取截至 2023 年 2 月 18 日发表的随机临床试验(RCT)。我们将大核心梗死患者定义为 Alberta Stroke Program 早期计算机断层扫描评分(ASPECTS)为 3-5。主要结局为功能独立性,定义为 90 天时改良 Rankin 量表(mRS)评分 0-2。次要结局为 90 天时独立行走,定义为 mRS 0-3。安全性结局为 90 天死亡率、症状性颅内出血(sICH)和任何颅内出血(ICH)。
总体治疗效果对 EVT 组更为有利。EVT 与 90 天时功能独立性改善(mRS 0-2)(RR=2.40;95%CI,1.82-3.16;P<0.01;I=0%)和独立行走(mRS 0-3)(RR=1.78;95%CI,1.28-2.48;P<0.01;I=58%)显著相关。两组 90 天死亡率无显著差异(RR=0.95;95%CI,0.78-1.16;P>0.05;I=0%)。EVT 组 sICH 和任何 ICH 的风险高于 BMM 组。
与 BMM 相比,EVT 可能改善 ASPECTS 3-5 的患者的功能结局,但与 sICH 和任何 ICH 的风险增加相关。